Skip to main content
. 2013 May 20;31(19):2469–2476. doi: 10.1200/JCO.2012.47.0500

Table A3.

Clinical Characteristics and Overall Survival of the Four Major Categories of SMNs in the Subset of 201 Patients Who Were Not Irradiated and Did Not Undergo Hematopoietic Stem-Cell Transplantation as Part of Their First-Line Treatment for ALL

Type of Second Cancer Total
Males
ALL Immunophenotype* (n = 192)
Age at ALL (years)
WBC at ALL (×109/L)
Interval to SMN (years)
Age at SMN (years)
5-Year Survival Rate After SMN (%)
No. % No. % BCP % Median 50% Range Median 50% Range Median 50% Range Median 50% Range
Total 201 107 53.2 173 90.1 3.6 2.3-6.6 9.0 6.5-15.1 44.1 ± 3.7
Hematologic 145 72.1 79 54.5 130 92.2 4.3 3.0-6.5 6.1 4.0-15.3 2.9 2.1-4.3 8.2 6.0-12.7 41.1 ± 4.2
CNS tumor 12 6.0 6 50.0 9 90.0 5.0 3.5-8.9 7.4 3.7-34.4 6.8 2.7-7.4 13.1 8.7-17.2 32.1 ± 15.0
Carcinoma 19 9.5 7 36.8 15 83.3 4.7 3.0-8.7 6.6 3.3-38.5 11.8 6.1-16.1 16.2 10.7-23.4 77.4 ± 10.0
Other 25 12.4 15 60.0 19 82.6 5.7 3.4-8.1 4.9 2.5-26.2 7.8 4.4-9.8 14.0 10.4-17.9 44.9 ± 11.3

Abbreviations: ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; SMN, second malignant neoplasm.

*

Nine patients were excluded because immunophenotype was not reported (n = 8) or was not specified as either BCP or T-cell ALL (n = 1).

Seventy-one acute myeloid leukemia, 38 myelodysplastic syndrome, three chronic myeloid leukemia, 23 non-Hodgkin lymphoma, 10 Hodgkin disease, 10 nonmeningioma CNS tumors, two meningioma, 10 nonthyroid carcinoma, nine thyroid carcinoma, seven soft tissue sarcoma, 12 bone tumors, one germ cell tumor, four Langerhans cell histiocytosis, one other tumor.